Starling Oncology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Starling Oncology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 70.81K shares, a 97.15% decline year-over-year.
- Starling Oncology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 25.33K shares, a 84.22% decline year-over-year.
- Starling Oncology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 336.82K shares.
- Starling Oncology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-06-30 was 2.48M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 70.81K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | |
| 2026-03-31 | 25.33K shares 10-Q · filed 2026-05-07 | |
| 2025-09-30 | 336.82K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | |
| 2025-06-30 | 2.48M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | |
| 2025-03-31 | 160.54K shares 10-Q · filed 2026-05-07 | |
| 2023-09-30 | 14.62K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | |
| 2022-09-30 | 93.70K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 |